Page 233 - Genentech News Today

/PRNewswire/ -- The Global Diabetic Retinopathy Market is anticipated to reach a valuation of USD 10329.7 million from USD 6647.3 million in 2021. It is...

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased

The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected

Stanford is investigating its president Marc Tessier-Lavigne over allegations that papers on which he is a co-author include altered images.

The proposed case accuses Roche Laboratories and Genentech of intentionally misleading the federal government about mefloquine. The judge said the lawsuit should not be filed in California.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. service members has been thrown out.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for ...

Marc Tessier-Lavigne faces years of allegations of scientific misconduct in his research, including papers he co-authored containing images which researchers…

The manufacturer has voluntarily withdrawn the US indication that covered its use in certain patients with bladder and urinary tract cancers.

LOS ANGELES (AP) — A federal judge threw out a lawsuit against the maker of an anti-malarial drug blamed for causing psychotic behavior and neurological damage to U.S. servicemembers, ruling that the case had no right to be filed in California.